Even the most reluctant among us are coming around to social media, with 2.31 billion users now active on social media globally. Still pharmaceutical and biotech companies have been slow to embrace social media for clinical trials. Why?
patient recruitment for clinical trials
In my previous post, I discussed ways to navigate some of the roadblocks that may impede your ability to enrol patients during the summer months. With those strategies firmly in place, it’s important to take advantage of a slow-down in activities to plan for the future.
The summer season is fast approaching and that can only mean one thing – summer holidays. There is one sure thing to cause frustration and delays in reaching your vacation destination – roadblocks. Whilst on holiday, I tend to do all of the driving and I know that in order to reduce the chances of getting caught up in traffic jams, highway repairs, and other unexpected delays, I need to plan my route in advance. The same approach applies to patient recruitment in global clinical trials.
Multiple Sclerosis is a complex disease affecting an estimated 2.5 million people globally. Thankfully, MS research is abundant, with 16 therapies approved by the FDA today and more than 30 in the pipeline.
From long-distance travel to busy schedules, participating in a clinical trial can be very difficult for patients, especially those living with a rare disease. Because of the complexity of rare diseases, patients and their caregivers must often travel long distances to see investigators who treat their unique disorder.
Two of UBC’s experts will offer attendees at next week’s CHI Summit for Clinical Ops Executives (SCOPE) a look at the ways we’re utilizing data to recruit for clinical trials.
Twenty nine million Americans are living with diabetes; that’s 1 out of every 11 people. The Centers for Disease Control and Prevention predicts a staggering growth in the disease’s prevalence: by 2050, 1 in 3 Americans will have diabetes.
To tackle the growing challenges of this disease, many of our manufacturer partners are working hard to develop new and innovative options that treat the disease and improve the quality of life for patients. However, many sponsors find that diabetes studies are difficult to enroll due to a variety of factors.
Even with all of the advances across the clinical research marketplace – EMR, social media, big data, mobile technology — the success of patient enrollment remains largely with the study site. So how can sponsors and sites work together to achieve enrollment goals?
Any good scientist should know that in order to keep up, you must constantly evolve your techniques. That’s especially true in the realm of clinical development, where balancing the challenges of patient-centric clinical trials with increasingly tighter budgets and shorter timelines is paramount to success.
UBC’s experts are here to help. In our free whitepaper, “Nine Evolutions in Clinical Research & Patient Recruitment: A 2016 Preview,” we share an in-depth look at the trends driving clinical trial participation.
It’s hard to foresee the challenges that come with recruiting patients for clinical trials, unless you have extensive expertise to lean on. UBC’s Patient and Physician Services (PPS) team has supported every major MS drug in the clinical pipeline over the last 17 years. We know how to get the right patients at the right sites for your next MS study.